Talee Bio Receives $4.5 Million from the Cystic Fibrosis Foundation to Expedite Development of Two Gene Therapy Candidates

Talee Bio, Inc. announced on 1/23/19 agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102.